Published in Cancer Immunol Res on July 08, 2015
Dendritic Cell Activating Scaffold in Melanoma | NCT01753089
Biomaterials for enhancing anti-cancer immunity. Curr Opin Biotechnol (2016) 0.85
Self-assembling peptides epitopes as a novel platform for anti-cancer vaccination. Mol Pharm (2017) 0.75
Enhancing vaccine effectiveness with delivery technology. Curr Opin Biotechnol (2016) 0.75
Biomaterials Strategies for Generating Therapeutic Immune Responses. Adv Drug Deliv Rev (2017) 0.75
CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. Oncogene (2017) 0.75
Tissue engineering. Science (1993) 19.65
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
T-cell function and migration. Two sides of the same coin. N Engl J Med (2000) 6.47
The future of immune checkpoint therapy. Science (2015) 5.59
Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity (2003) 5.52
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity (2008) 5.22
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol (2010) 4.06
Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med (2012) 3.99
Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol (2007) 3.75
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature (2015) 3.46
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature (2014) 3.42
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater (2011) 2.71
Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat Med (2013) 2.65
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer (2008) 2.31
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15
BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg (1974) 2.14
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release (2006) 2.05
Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology (2006) 1.92
Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol (2014) 1.77
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med (2012) 1.74
In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1.65
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Structure-based programming of lymph-node targeting in molecular vaccines. Nature (2014) 1.60
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med (2014) 1.52
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A (2012) 1.51
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater (2010) 1.45
Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 1.39
Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res (1990) 1.22
Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol (2005) 1.22
Nanoparticle delivery systems in cancer vaccines. Pharm Res (2010) 1.20
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20
Rational design of small molecules as vaccine adjuvants. Sci Transl Med (2014) 1.20
In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res (2000) 1.20
Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci U S A (2001) 1.19
Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response. Biomaterials (2013) 1.13
Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS One (2013) 1.12
Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater (2012) 1.12
Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol (2005) 1.11
Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res (2013) 1.11
Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med (2013) 1.09
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04
Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest (2015) 1.03
Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction. Vaccine (2011) 1.03
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials (2011) 1.02
Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine (2014) 1.02
Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology (2014) 1.01
Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat Biotechnol (2002) 0.98
Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today Technol (2005) 0.98
Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy. Nat Biotechnol (2014) 0.95
Personal neoantigen cancer vaccines: The momentum builds. Oncoimmunology (2014) 0.91
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials (2009) 0.86
Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release (2011) 0.85
Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin Cancer Res (2003) 0.83
Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine (2012) 0.83
The efficacy of intracranial PLG-based vaccines is dependent on direct implantation into brain tissue. J Control Release (2011) 0.79
A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year. Biomaterials (2015) 0.78